Literature DB >> 31223249

Anxiolytic-Like and Antidepressant-Like Effects of Resveratrol in Streptozotocin-Induced Diabetic Rats.

Tuğçe Demirtaş Şahin1, Semil Selcen Göçmez1, Fatma Ceyla Eraldemir2, Tijen Utkan1.   

Abstract

INTRODUCTION: Diabetes is associated with anxiety and depression. Resveratrol, one of the most potent natural polyphenols with antioxidant properties, has been demonstrated to have benefits against diabetes. In the current study, we investigated the effects of resveratrol on depression and anxiety-like behaviors in diabetic rats.
METHODS: Adult male Wistar albino rats were assigned for control and diabetic groups, and these groups were divided into four subgroups as follows: Saline-treated, DMSO-treated, resveratrol-treated and imipramine-treated animals (n=10). Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ) (50 mg/kg), and 2 days after the STZ injection the rats having hyperglycemia (>300 mg/dl) were assigned to be diabetic. Rats in treatment groups were injected intraperitoneally with resveratrol (20 mg/kg) and imipramine (10 mg/kg) for 4 weeks. After 4-week-treatment period, tail suspension test (TST), forced swimming test (FST), elevated plus maze test (EPM) and locomotor activity test were performed. Blood samples were collected to estimate serum superoxide dismutase (SOD) and NADPH oxidase (Nox) levels.
RESULTS: Diabetic rats displayed depressive-like behaviors in the FST and TST, and anxiety-like behaviors in the EPM. Resveratrol and imipramine decreased anxiety-like and depressive-like behaviors without affecting locomotor activity in diabetic rats. A significant reduction in SOD levels and a marked increase in Nox levels were observed in diabetic rats. Resveratrol treatment normalized these levels, while imipramine did not affect neither SOD nor Nox levels.
CONCLUSION: This study indicates that chronic resveratrol treatment may able to treat comorbid anxiety-and depressive-like behaviors in diabetes through inhibition of oxidative stress.

Entities:  

Keywords:  Diabetes; anxiety; depression; resveratrol

Year:  2019        PMID: 31223249      PMCID: PMC6563862          DOI: 10.29399/npa.23176

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  29 in total

1.  Antidepressant-like effect of leptin in streptozotocin-induced diabetic mice.

Authors:  Shoko Hirano; Shigeo Miyata; Junzo Kamei
Journal:  Pharmacol Biochem Behav       Date:  2006-12-20       Impact factor: 3.533

2.  Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats.

Authors:  Hui-Chen Su; Li-Man Hung; Jan-Kan Chen
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-01-24       Impact factor: 4.310

3.  Antidepressant-like effect of trans-resveratrol: Involvement of serotonin and noradrenaline system.

Authors:  Ying Xu; Zhichao Wang; Wenting You; Xiuhua Zhang; Shan Li; Philip A Barish; Matthew M Vernon; Xia Du; Gaowen Li; Jianchun Pan; William O Ogle
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-30       Impact factor: 4.600

Review 4.  Diabetes, oxidative stress, and antioxidants: a review.

Authors:  A C Maritim; R A Sanders; J B Watkins
Journal:  J Biochem Mol Toxicol       Date:  2003       Impact factor: 3.642

Review 5.  Cytokines and major depression.

Authors:  Olga J G Schiepers; Marieke C Wichers; Michael Maes
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-01-25       Impact factor: 5.067

6.  Exploring the relationship between diabetes self-efficacy, depressive symptoms, and glycemic control among men and women with type 2 diabetes.

Authors:  Andrea Cherrington; Kenneth A Wallston; Russell L Rothman
Journal:  J Behav Med       Date:  2010-02

7.  Hippocampal neurovascular and hypothalamic-pituitary-adrenal axis alterations in spontaneously type 2 diabetic GK rats.

Authors:  Juan Beauquis; Françoise Homo-Delarche; Marie-Hélène Giroix; Jan Ehses; Josiane Coulaud; Paulina Roig; Bernard Portha; Alejandro F De Nicola; Flavia Saravia
Journal:  Exp Neurol       Date:  2010-01-04       Impact factor: 5.330

Review 8.  Experimental animal models for the simulation of depression and anxiety.

Authors:  Eberhard Fuchs; Gabriele Flïugge
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 9.  Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium.

Authors:  Miranda T Schram; Caroline A Baan; François Pouwer
Journal:  Curr Diabetes Rev       Date:  2009-05

10.  Depression and body mass index, a u-shaped association.

Authors:  Leonore M de Wit; Annemieke van Straten; Marieke van Herten; Brenda W J H Penninx; Pim Cuijpers
Journal:  BMC Public Health       Date:  2009-01-13       Impact factor: 3.295

View more
  3 in total

1.  Antidiabetic effects of Scrophularia striata ethanolic extract via suppression of Pdx1 and Ins1 expression in pancreatic tissues of diabetic rats.

Authors:  Armieti Babaiedarzi; Saba Ghanbari; Maryam Mehrad Seresht; Modara Nasiri
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

Review 2.  Mitophagy in depression: Pathophysiology and treatment targets.

Authors:  Ashutosh Tripathi; Giselli Scaini; Tatiana Barichello; João Quevedo; Anilkumar Pillai
Journal:  Mitochondrion       Date:  2021-08-31       Impact factor: 4.160

3.  Mucuna pruriens Administration Minimizes Neuroinflammation and Shows Anxiolytic, Antidepressant and Slimming Effects in Obese Rats.

Authors:  Renata Leite Tavares; Maria Helena Araújo de Vasconcelos; Maria Letícia da Veiga Dutra; Aline Barbosa D'Oliveira; Marcos Dos Santos Lima; Mirian Graciela da Silva Stiebbe Salvadori; Ramon de Alencar Pereira; Adriano Francisco Alves; Yuri Mangueira do Nascimento; Josean Fechine Tavares; Omar Guzman-Quevedo; Jailane de Souza Aquino
Journal:  Molecules       Date:  2020-11-26       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.